Login / Signup

Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.

Magdalena Knetki-WroblewskaDariusz M KowalskiGrzegorz CzyżewiczMaciej BrylAnna WronaRafał DziadziuszkoRobert KieszkoJanusz MilanowskiDaria ŚwiniuchRodryg RamlauMaciej Krzakowski
Published in: Advances in respiratory medicine (2021)
These results confirm the value of osimertinib in patients with previously treated EGFR T790M-mutant NSCLC. Clinical benefit was evident in patients with cerebral metastases and moderate performance status.
Keyphrases